SAB Gross Profit from 2010 to 2025

SABSW Stock

USD 0.03 0.01 20.85%

SAB Biotherapeutics Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit SAB Biotherapeutics makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-1.4 M

Current Value

-1.3 M

Quarterly Volatility

19 M

Credit Downgrade

Yuan Drop

Covid

Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 4.5 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 18.54, Dividend Yield of 0.0 or PTB Ratio of 0.63. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.

Check out the analysis of SAB Biotherapeutics Correlation against competitors.

For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Latest SAB Biotherapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of SAB Biotherapeutics over the last few years. Gross profit is a required income statement account that reflects total revenue of SAB Biotherapeutics minus its cost of goods sold. It is profit before SAB Biotherapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. SAB Biotherapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (25.38 M)

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

SAB Gross Profit Regression Statistics

	Arithmetic Mean	10,333,799
	Coefficient Of Variation	183.59
	Mean Deviation	13,008,893
	Median	3,441,807
	Standard Deviation	18,971,921
	Sample Variance	359.9T
	Range	60.7M
	R-Value	0.23
	Mean Square Error	365.7T
	R-Squared	0.05
	Significance	0.40
	Slope	906,232
	Total Sum of Squares	5399T

SAB Gross Profit History

	2025	-1.3 M
	2024	-1.4 M
	2023	-1.5 M
	2022	20.6 M
	2021	59.2 M
	2020	55.2 M

Other Fundumenentals of SAB Biotherapeutics

Gross Profit Margin

SAB Biotherapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue
Total Assets		0.99	-0.91	-0.68	0.06	0.92	0.1	0.73	0.99	-0.77	0.99	-0.75	0.88	-0.31	-0.55	0.73
Total Stockholder Equity	0.99		-0.89	-0.68	0.09	0.9	0.15	0.61	1.0	-0.73	0.97	-0.74	0.88	-0.22	-0.56	0.74
Net Debt	-0.91	-0.89		0.88	0.3	-0.91	0.23	-0.7	-0.9	0.58	-0.93	0.94	-0.96	0.11	0.78	-0.92
Retained Earnings	-0.68	-0.68	0.88		0.63	-0.76	0.57	-0.42	-0.69	0.19	-0.7	0.95	-0.82	-0.32	0.83	-0.93
Accounts Payable	0.06	0.09	0.3	0.63		-0.1	0.98	-0.09	0.08	-0.49	-0.01	0.55	-0.23	-0.63	0.56	-0.5
Long Term Debt	0.92	0.9	-0.91	-0.76	-0.1		-0.09	0.71	0.9	-0.76	0.87	-0.78	0.85	-0.17	-0.5	0.76
Net Receivables	0.1	0.15	0.23	0.57	0.98	-0.09		-0.13	0.14	-0.48	0.05	0.46	-0.13	-0.58	0.42	-0.4
Total Liab	0.73	0.61	-0.7	-0.42	-0.09	0.71	-0.13		0.61	-0.71	0.73	-0.55	0.6	-0.55	-0.31	0.46
Net Invested Capital	0.99	1.0	-0.9	-0.69	0.08	0.9	0.14	0.61		-0.72	0.97	-0.75	0.88	-0.21	-0.57	0.75
Short Long Term Debt	-0.77	-0.73	0.58	0.19	-0.49	-0.76	-0.48	-0.71	-0.72		-0.69	0.32	-0.57	0.7	0.07	-0.31
Total Current Assets	0.99	0.97	-0.93	-0.7	-0.01	0.87	0.05	0.73	0.97	-0.69		-0.79	0.9	-0.27	-0.63	0.77
Capital Stock	-0.75	-0.74	0.94	0.95	0.55	-0.78	0.46	-0.55	-0.75	0.32	-0.79		-0.94	-0.16	0.92	-0.99
Net Working Capital	0.88	0.88	-0.96	-0.82	-0.23	0.85	-0.13	0.6	0.88	-0.57	0.9	-0.94		-0.06	-0.85	0.95
Short Term Debt	-0.31	-0.22	0.11	-0.32	-0.63	-0.17	-0.58	-0.55	-0.21	0.7	-0.27	-0.16	-0.06		-0.27	0.22
Common Stock	-0.55	-0.56	0.78	0.83	0.56	-0.5	0.42	-0.31	-0.57	0.07	-0.63	0.92	-0.85	-0.27		-0.94
Current Deferred Revenue	0.73	0.74	-0.92	-0.93	-0.5	0.76	-0.4	0.46	0.75	-0.31	0.77	-0.99	0.95	0.22	-0.94

Click cells to compare fundamentals

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics investors use historical fundamental indicators, such as SAB Biotherapeutics' Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in SAB Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	-1.4 M	-1.3 M
Gross Profit Margin	(0.77)	(0.73)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC